PP
MDGL icon

PDT Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

PDT Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,524
Closed -$424K – 789
2022
Q3 		$424K Buy
6,524
+1,955
+43% +$136K 0.06% 482
2022
Q2 		$327K Buy
+4,569
New +$336K 0.03% 719
2022
Q1 		– Sell
-2,535
Closed -$215K – 1039
2021
Q4 		$215K Buy
+2,535
New +$208K 0.02% 750

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDT Partners's MDGL Position: Q4 2022 in Review

PDT Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2022, closing a stake of 6,524 shares — an estimated $424K sold.

PDT Partners first reported a position in MDGL in Q4 2021 and held it in 3 quarters. The position peaked at $424K in Q3 2022. 188 funds tracked by Wall St. Rank hold MDGL as of Q4 2022.

  • PDT Partners reported no remaining Madrigal Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • PDT Partners sold 6,524 Madrigal Pharmaceuticals shares in Q4 2022, an estimated $424K.
  • PDT Partners first reported a position in Madrigal Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • PDT Partners's Madrigal Pharmaceuticals position peaked at $424K in Q3 2022.
  • 188 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.